long-term effects of glp-1 receptor agonists glp 1 gip side gip medications long term effects Managing Side Effects switching glp 1 agonists GLP-1

Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE

These changes persisted or were only partially reversible except for the changes caused by empagliflozin and sotagliflozin which showed full reversibility upon discontinuation

Prates C , Sousa S, Oliveira C, Ikram S

Free testosterone levels drop significantly during treatment, and these benefits often remain stable even after stopping GLP-1 therapy, provided metformin is continued

heart muscle function), and blood circulation

Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026